Trial Profile
A two-part study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat oral doses of GSK256073A, in a randomized, single-blind, dose escalation study in healthy adult subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 256073 (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors GSK
- 18 Jun 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.
- 17 Jul 2007 New trial record.